Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$28.29 USD
-0.18 (-0.63%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $28.33 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Cash flow Statements
Fiscal Year End for Myriad Genetics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -263.30 | -112.00 | -27.20 | -59.40 | -199.50 |
Depreciation/Amortization & Depletion | 61.90 | 69.60 | 64.60 | 35.80 | 72.00 |
Net Change from Assets/Liabilities | 10.70 | -101.50 | 120.40 | -131.60 | 115.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 79.80 | 37.60 | -139.60 | 82.20 | 73.10 |
Net Cash From Operating Activities | -110.90 | -106.30 | 18.20 | -73.00 | 60.70 |
Property & Equipment | -63.20 | -45.30 | -18.00 | -8.20 | -10.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -57.20 | 379.10 | 21.30 | 21.30 |
Investments | 105.20 | 25.00 | -86.70 | 35.90 | 8.20 |
Other Investing Activities | -10.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 31.90 | -77.50 | 274.40 | 27.70 | 19.30 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 123.60 | 6.30 | 91.80 | 1.80 | 3.50 |
Issuance (Repayment) of Debt | 39.80 | 0.00 | -226.40 | -8.60 | -8.60 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -10.50 | -14.30 | -16.00 | -3.90 | -4.90 |
Net Cash from Financing Activities | 152.90 | -8.00 | -150.60 | -2.10 | -10.00 |
Effect of Exchange Rate Changes | 0.60 | -0.60 | -0.60 | 0.70 | 0.50 |
Net Change In Cash & Equivalents | 74.50 | -192.40 | 141.40 | -46.70 | 70.50 |
Cash at Beginning of Period | 66.40 | 258.80 | 117.00 | 163.70 | 93.20 |
Cash at End of Period | 140.90 | 66.40 | 258.40 | 117.00 | 163.70 |
Diluted Net EPS | -3.18 | -1.39 | -0.35 | -2.69 | -2.69 |
Fiscal Year End for Myriad Genetics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -62.70 | -26.00 | -263.30 | -232.10 | -170.80 |
Depreciation/Amortization & Depletion | 43.60 | 16.90 | 61.90 | 46.80 | 32.70 |
Net Change from Assets/Liabilities | -22.90 | -20.60 | 10.70 | 84.60 | 74.80 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 26.00 | 11.10 | 79.80 | 44.50 | 29.20 |
Net Cash From Operating Activities | -16.00 | -18.60 | -110.90 | -56.20 | -34.10 |
Property & Equipment | -11.90 | -6.70 | -63.20 | -53.20 | -42.30 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.00 | 1.50 | 105.20 | 103.70 | 88.70 |
Other Investing Activities | -5.60 | -1.90 | -10.10 | -6.60 | 0.00 |
Net Cash from Investing Activities | -13.50 | -7.10 | 31.90 | 43.90 | 46.40 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.00 | 0.00 | 123.60 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | -0.20 | -0.10 | 39.80 | 39.90 | 40.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -9.20 | -8.70 | -10.50 | -8.90 | -6.50 |
Net Cash from Financing Activities | -6.40 | -8.80 | 152.90 | 31.00 | 33.50 |
Effect of Exchange Rate Changes | -3.80 | -0.80 | 0.60 | -0.10 | 0.50 |
Net Change In Cash & Equivalents | -39.70 | -35.30 | 74.50 | 18.60 | 46.30 |
Cash at Beginning of Period | 140.90 | 140.90 | 66.40 | 66.40 | 66.40 |
Cash at End of Period | 101.20 | 105.60 | 140.90 | 85.00 | 112.70 |
Diluted Net EPS | -0.41 | -0.29 | -0.34 | -0.75 | -1.42 |